Cara Therapeutics Stock Forecast, Price & News

+0.95 (+8.23 %)
(As of 08/5/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume1.05 million shs
Average Volume843,207 shs
Market Capitalization$625.65 million
P/E Ratio54.35
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive CARA News and Ratings via Email

Sign-up to receive the latest news and ratings for Cara Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Cara Therapeutics logo

About Cara Therapeutics

Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP) undergoing hemodialysis. The company is also developing Oral KORSUVA (CR845/difelikefalin), which has completed Phase II clinical trial for the treatment of pruritus in stage III-V CKD patients; in Phase II clinical trial for treating pruritus chronic liver disease; and in Phase II clinical trial for the treatment of pruritus associated with atopic dermatitis. In addition, it is developing CR845/difelikefalin Injection, which has completed Phase II/III clinical trial for the treatment of acute post-operative pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845/difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845/difelikefalin in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.29 out of 5 stars

Medical Sector

259th out of 1,311 stocks

Pharmaceutical Preparations Industry

127th out of 647 stocks

Analyst Opinion: 3.3Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Cara Therapeutics (NASDAQ:CARA) Frequently Asked Questions

Is Cara Therapeutics a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cara Therapeutics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Cara Therapeutics stock.
View analyst ratings for Cara Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Cara Therapeutics?

Wall Street analysts have given Cara Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Cara Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Cara Therapeutics' next earnings date?

Cara Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Cara Therapeutics

How can I listen to Cara Therapeutics' earnings call?

Cara Therapeutics will be holding an earnings conference call on Monday, August 9th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Cara Therapeutics' earnings last quarter?

Cara Therapeutics, Inc. (NASDAQ:CARA) released its quarterly earnings data on Sunday, May, 9th. The biopharmaceutical company reported ($0.47) earnings per share for the quarter, topping analysts' consensus estimates of ($0.59) by $0.12. The biopharmaceutical company had revenue of $1.94 million for the quarter, compared to analysts' expectations of $10.15 million. Cara Therapeutics had a net margin of 10.88% and a trailing twelve-month return on equity of 7.50%.
View Cara Therapeutics' earnings history

How has Cara Therapeutics' stock been impacted by Coronavirus (COVID-19)?

Cara Therapeutics' stock was trading at $13.43 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CARA stock has decreased by 6.9% and is now trading at $12.50.
View which stocks have been most impacted by COVID-19

What price target have analysts set for CARA?

3 analysts have issued 12 month price targets for Cara Therapeutics' shares. Their forecasts range from $16.00 to $30.00. On average, they expect Cara Therapeutics' share price to reach $24.00 in the next twelve months. This suggests a possible upside of 92.0% from the stock's current price.
View analysts' price targets for Cara Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Cara Therapeutics' key executives?

Cara Therapeutics' management team includes the following people:
  • Dr. Derek T. Chalmers, Co-Founder, Pres, CEO & Director (Age 57, Pay $1.02M)
  • Mr. Thomas Charles Reilly, Chief Financial Officer (Age 49, Pay $170.59k)
  • Mr. Richard Makara, VP, Head of Accounting, Controller & Principal Accounting Officer (Age 50, Pay $420.43k)
  • Dr. Frédérique Menzaghi, Chief Scientific Officer and Sr. VP of R&D (Age 55, Pay $785.51k)
  • Mr. Scott M. Terrillion, Chief Compliance Officer, Gen. Counsel & Corp. Sec. (Age 58, Pay $587.88k)
  • Dr. Joana Goncalves, Chief Medical Officer (Age 47, Pay $732.9k) (LinkedIn Profile)
  • Dr. Michael E. Lewis, Co-Founder & Chief Scientific Advisor (Age 69)
  • Mr. Eric Vandal, Sr. VP of Commercial

Who are some of Cara Therapeutics' key competitors?

What other stocks do shareholders of Cara Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cara Therapeutics investors own include Lions Gate Entertainment (LGF.A), (CGC), Zynerba Pharmaceuticals (ZYNE), Puma Biotechnology (PBYI), GW Pharmaceuticals (GWPH), 22nd Century Group (XXII), Novavax (NVAX), INSYS Therapeutics (INSY), Fate Therapeutics (FATE) and Incyte (INCY).

What is Cara Therapeutics' stock symbol?

Cara Therapeutics trades on the NASDAQ under the ticker symbol "CARA."

Who are Cara Therapeutics' major shareholders?

Cara Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include C WorldWide Group Holding A S (1.17%), Pinnacle Associates Ltd. (0.70%), Rhumbline Advisers (0.30%), Davy Global Fund Management Ltd (0.15%), Alliancebernstein L.P. (0.11%) and Russell Investments Group Ltd. (0.10%). Company insiders that own Cara Therapeutics stock include Christopher Posner, Derek T Chalmers, Frederique PhD Menzaghi, Jeffrey L Ives, Joana Goncalves, Mani Mohindru, Martin Vogelbaum and Scott Terrillion.
View institutional ownership trends for Cara Therapeutics

Which institutional investors are selling Cara Therapeutics stock?

CARA stock was sold by a variety of institutional investors in the last quarter, including C WorldWide Group Holding A S, Victory Capital Management Inc., Russell Investments Group Ltd., Rathbone Brothers plc, Arizona State Retirement System, Advisor Group Holdings Inc., Freedman Financial Associates Inc., and Rothschild Investment Corp IL. Company insiders that have sold Cara Therapeutics company stock in the last year include Christopher Posner, Derek T Chalmers, Frederique PhD Menzaghi, Joana Goncalves, Martin Vogelbaum, and Scott Terrillion.
View insider buying and selling activity for Cara Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Cara Therapeutics stock?

CARA stock was acquired by a variety of institutional investors in the last quarter, including Rhumbline Advisers, Exchange Traded Concepts LLC, Texas Permanent School Fund, State of Alaska Department of Revenue, Davy Global Fund Management Ltd, Oregon Public Employees Retirement Fund, 6 Meridian, and Handelsbanken Fonder AB.
View insider buying and selling activity for Cara Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Cara Therapeutics?

Shares of CARA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cara Therapeutics' stock price today?

One share of CARA stock can currently be purchased for approximately $12.50.

How much money does Cara Therapeutics make?

Cara Therapeutics has a market capitalization of $625.65 million and generates $135.08 million in revenue each year. The biopharmaceutical company earns $8.41 million in net income (profit) each year or $0.18 on an earnings per share basis.

How many employees does Cara Therapeutics have?

Cara Therapeutics employs 80 workers across the globe.

What is Cara Therapeutics' official website?

The official website for Cara Therapeutics is

Where are Cara Therapeutics' headquarters?

Cara Therapeutics is headquartered at 107 ELM STREET 9TH FLOOR, STAMFORD CT, 06902.

How can I contact Cara Therapeutics?

Cara Therapeutics' mailing address is 107 ELM STREET 9TH FLOOR, STAMFORD CT, 06902. The biopharmaceutical company can be reached via phone at 203-406-3700 or via email at [email protected]

This page was last updated on 8/5/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.